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a b s t r a c t
Myeloproliferative neoplasms transformed into AML usually have a poor prognosis. We report a case of
essential thrombocythemia with myeloﬁbrosis that transformed into acute promyelocytic leukemia
(APL) with both the t(15;17) translocation as well as the JAK2 V617F mutation. Clinically, this case was
notable for severe differentiation syndrome despite treatment with high-dose dexamethasone. Cytokine
production by differentiating APL cells was not directly abrogated by JAK2 inhibitors in vitro, suggesting
that JAK2 V617F enhances the hyperinﬂammatory response downstream of cytokines. JAK1/2 inhibitors
may therefore dampen the inﬂammatory cascade downstream of cytokine production, similar to
glucocorticoids, and have a role in treating severe differentiation syndrome.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Essential thrombocythemia (ET) is a clonal disorder of the
hematopoietic stem cell that is closely related to two other
myeloproliferative neoplasms (MPNs) polycythemia vera (PV)
and primary myeloﬁbrosis (PMF). The Janus-Associated-Kinase 2
(JAK2) V617F mutation is present in the vast majority of PV
patients and in 50% of patients with ET and PMF [1]. JAK2 V617F
produces constitutive activation of the thrombopoietin and ery-
thropoietin signaling pathways, driving ET and PV respectively.
Over time, ET and PV can both progress to myeloﬁbrosis [1].
Further, all three conditions can transform into acute myelogenous
leukemia (AML), although this occurs most frequently in PMF [2].
Transformation carries a dismal prognosis [2] and is often asso-
ciated with complex genetic changes. Transformation of ET, PV or
PMF into acute promyelocytic leukemia (APL), a favorable risk
leukemia characterized by the t(15;17) translocation, is exceed-
ingly rare with only eight documented cases in the literature [3–9].
Of these, only two prior cases have been reported of ET transform-
ing into APL with molecular documentation of t(15;17) [3,4]. We
report an 83-year-old woman with a history of ET and progression
to myeloﬁbrosis, who then transformed to APL. To our knowledge,
this is the ﬁrst case to demonstrate co-expression of PML-RARα
and JAK2 V617F by leukemic blasts. Clinically she also developed
severe differentiation syndrome during induction with ATRA plus
arsenic trioxide (ATO), suggesting that JAK2 signaling may aug-
ment differentiation syndrome.
2. Case study
The patient was diagnosed with ET in 1995 and began treat-
ment with hydroxyurea and aspirin. In 2011 she noted worsening
fatigue and left lower quadrant abdominal pain. She underwent a
bone marrow biopsy that revealed myeloﬁbrosis with a JAK2
V617F allelic burden of 92% and was found to have splenomegaly.
Treatment with the JAK1/2 inhibitor ruxolitinib was initiated,
which resulted in a signiﬁcant improvement in energy and
appetite. She did well until May of 2013 when she was noted to
be pancytopenic with a WBC of 2.0 103/mm3, hemoglobin of
8.5 mg/dL and platelets of 96103/mm3. Concerned that her
cytopenias were the result of ruxolitinib, it was discontinued;
however, she remained persistently pancytopenic. A bone marrow
biopsy revealed a hypercellular marrow with 70% blasts, mega-
karyocytic hyperplasia and grade 3/3 ﬁbrosis. Fluorescence in-situ
hybridization (FISH) conﬁrmed the t(15;17) in 90% of cells and
diagnosis of APL. A GeneTrails AML/MDS next-generation sequen-
cing panel (Supplementary Table 1, Knight Diagnostics Lab, Port-
land, OR) was performed on marrow aspirate and was signiﬁcant
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for a JAK2 V617F allelic burden of 90%, indicating that the APL
cells also contained the JAK2 V617F mutation. A FLT3 D835
mutation was also found with this panel.
Given her advanced age she was started on ATRAþarsenic
trioxide (ATO) induction [10]. After two days of ATRA her WBC
count began to increase rapidly and despite escalating doses of
hydroxyurea her WBC count continued to rise, reaching 67.4103/
mm3 on day 6 of ATRA (Fig. 1A,B). During this time she was started
on treatment-dose dexamethasone for differentiation syndrome.
She developed severe abdominal pain and ultrasound demon-
strated splenomegaly (15.86.813.7 cm). Despite dexametha-
sone, her symptoms were felt to be secondary to severe
differentiation syndrome and she was given a single dose of
idarubicin (12 mg/m2) for rapid cytoreduction. Her WBC count
peaked on day 7 at 95.9103/mm3. At this time she developed
increasing oxygen requirements with a chest X-ray demonstrating
evolving bilateral patchy opacities (Fig. 1C). Given her clinical
deterioration, ATRA was held for two days but by day 9 her WBC
had decreased to 27.5103/mm3. ATRA was restarted, hydro-
xyurea was tapered, and on day 10 ATO (0.15 mg/kg/day) was
initiated. However, despite her declining WBC count, her oxygen
requirement again increased to 10 L on day 12 and she was
aggressively diuresed in addition to continued dexamethasone.
By day 17 she showed dramatic clinical improvement and was
successfully weaned from oxygen. A repeat ultrasound at this time
demonstrated a greater than 50% reduction in splenic volume
(11.210.85.5 cm), suggesting that extramedullary APL cells
were abundant in the spleen and the bone marrow. A bone
marrow biopsy performed on day 34 revealed a morphologic
complete remission and she was discharged to a rehab facility to
recover. On day 47 after initiation of therapy, her peripheral blood
had counts recovered with a WBC count of 29.9103/mm3,
hemoglobin of 11.0 mg/dL and platelets of 603103/mm3, consis-
tent with her previous ET, so she was restarted on 10 mg twice daily
ruxolitinib and 81 mg aspirin. She then received four cycles of
consolidation therapy with ATRA plus ATO [10]. Ruxolitinib was
well tolerated during consolidation and dose reduced only when
her platelet count decreased with ATO. A bone marrow biopsy after
completion of consolidation revealed complete molecular remission
and a return to her underlying myeloproliferative disease with
grade 2/3 myeloﬁbrosis.
3. Discussion
ATRA and arsenic are both known to induce differentiation
syndrome but this case was notable for its severity. Previous
studies of differentiation syndrome have demonstrated that APL
cells treated with ATRA secrete the chemokines CCL2 and IL-8,
which in combination with chemokine production from alveolar
Fig. 1. Development of Severe Leukocytosis and Differentiation Syndrome. (A) Peripheral smear (40x) on day 2 of ATRA showing circulating promyelocyte with classic
bi-lobed nucleus and granules and later a mixture of promyelocytes with differentiating myeloid precursors on day 7. (B) Time course of WBC count during hospitalization
with demarcation of critical events. Dex¼Dexamethasone, Ida¼ Idarubicin, ATO¼Arsenic Trioxide. (C) Chest X-ray revealing bilateral patchy opacities consistent with
differentiation syndrome.
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epithelial cells, are thought to initiate a hyperinﬂammatory
cascade in the lung [11]. While dexamethasone does not directly
affect the production of CCL2 or IL-8 from APL cells, it does reduce
their production in the lung and thus attenuates the clinical
development of differentiation syndrome [11]. Since inﬂammatory
cytokine signaling plays a signiﬁcant role both in the pathogenesis
of JAK2 V617F MPNs as well as in the development of differentia-
tion syndrome, we postulated that robust differentiation syn-
drome experienced by this patient was the result of excessive
inﬂammatory response related to her underlying JAK2 V617F
mutation.
To test whether JAK2 inhibition has any direct effects on the
production of cytokines by APL cells, we used ATRA to differentiate
the NB-4 APL cell line in the presence or absence of ruxolitinib.
Cytokine release into the media was measured over three days of
ATRA-induced differentiation. There was a substantial increase in
both CCL2 and IL-8 with ATRA treatment, although this was not
abrogated by JAK inhibition (Fig. 2). In fact, ruxolitinib had very
little effect overall on cytokine production of NB-4 cells. Therefore,
CCL2 and IL-8 production by APL cells is unaffected by JAK
inhibition, similar to what has been shown for dexamethasone
[11]. However, there is substantial evidence that signaling down-
stream of cytokines is through activation of JAK2 [1]. Indeed, it is
possible that the presence of JAK2 V617F in APL and non-leukemic
cells enhances CCR2 and IL-8 signaling during differentiation
syndrome, accelerating leukocyte extravasation and inﬂammatory
ampliﬁcation within the lungs and other organs. This suggests that
JAK inhibitors may have clinical utility in attenuating the inﬂam-
matory ampliﬁcation step in differentiation syndrome in a manner
similar to glucocorticoids. Further studies with in vivo models of
differentiation syndrome are needed to evaluate this possibility.
In summary, this case details a previously undescribed patho-
logic entity, the co-expression of the PML/RARα and JAK2 V617F in
APL. Further, the clinical presentation with severe differentiation
syndrome may be the result of this rare molecular partnership,
providing a framework for future studies exploring the role of
JAK2 in differentiation syndrome. In so doing, it offers the
opportunity for the development of novel non-steroidal therapies
in the management of differentiation syndrome.
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